Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT06466785
- Locations
- 🇬🇪
Batumi Dialysis and Nephrology Center, Batumi, Georgia
🇬🇪L.Managadze National Center of Urology, Tbilisi, Georgia
🇬🇪Tbilisi Heart And Vascular Clinic, Tbilisi, Georgia
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 120
- Registration Number
- NCT05340465
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Rufaida Mazahir
- Target Recruit Count
- 50
- Registration Number
- NCT04959578
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 41
- Registration Number
- NCT04798339
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory-Winship Cancer Institute, Atlanta, Georgia, United States
Darbepoetin in Neonatal Encephalopathy Trial
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 150
- Registration Number
- NCT04432662
- Locations
- 🇬🇧
Birmingham Womens Hospital, Birmingham, United Kingdom
🇬🇧Imperial College Healthcare Trust, London, United Kingdom
🇬🇧Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 319
- Registration Number
- NCT04313153
- Locations
- 🇪🇸
Research Site, Valencia, Spain
🇪🇸Research Site #2, Barcelona, Spain
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- JW Pharmaceutical
- Target Recruit Count
- 172
- Registration Number
- NCT04027517
- Locations
- 🇰🇷
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
Desidustat in the Treatment of Anemia in CKD
- Conditions
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 588
- Registration Number
- NCT04012957
- Locations
- 🇮🇳
Sawai Man Singh (SMS) Medical College and Hospital, Jaipur, Rajasthan, India
🇮🇳Max Super Specialty Hospital, New Delhi, Delhi, India
🇮🇳Eternal Hospital, Jaipur, Rajasthan, India
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 46
- Registration Number
- NCT03992066
- Locations
- 🇺🇸
Research Site, Chattanooga, Tennessee, United States
Mechanisms of EPO-induced Hypertension
- Conditions
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 27
- Registration Number
- NCT03810911
- Locations
- 🇺🇸
Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.